Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACT01 + Comp04
- Development stage
- Unknown
- Lead developer
- Promius Pharma, LLC
- Administration
- Topical
01
Overview
ACT01 + Comp04 is an experimental combination therapy studied for the treatment of actinic keratosis. The therapy involves concurrent topical administration of ACT01 Cream and Comp04 Cream, applied once daily for a period of 29 days. The efficacy and tolerability of this combination were evaluated in a completed interventional clinical trial targeting actinic keratosis lesions on the face and/or scalp. Information on the precise composition, molecular targets, or mechanisms of ACT01 and Comp04 in this context has not been disclosed in available sources. The development and clinical evaluation of this combination was led by Promius Pharma.
- Other names
- ACT01 + Comp04
Beyond the preview
Go deeper on ACT01 + Comp04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACT01 + Comp04.